Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 13Gastrointestinal 9Thoracic 7Other hematologic neoplasm 6Genitourinary 5Tumor-Agnostic 3Gynecologic 3Sarcoma 2Plasma cell 2Other solid neoplasm 2Myeloid 2Head & Neck 2Dermatologic 2Lymphoid 1Endocrine 1Classical hematology 1

Conditions

Multiple Endocrine Neoplasia Type 1 1

Interventions

Everolimus 32Octreotide 15Cisplatin 14pasireotide 13Sunitinib 13Temozolomide 11pembrolizumab 10Etoposide 10Doxorubicin 10lanreotide 9Magnetic Resonance Spectroscopy 9Bevacizumab 9lutetium Lu 177 dotatate 8gallium Ga 68 dotatate 8Sorafenib 8Paclitaxel 83-Iodobenzylguanidine 8lenvatinib 7pazopanib 6Radiotherapy 6Positron Emission Tomography Computed Tomography 6surufatinib 5cabozantinib 5avelumab 5Thyrotropin Alfa 5Surgical Procedures, Operative 5Radiosurgery 5Nivolumab 5Mitotane 5Irinotecan 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Practice Guidelines as Topic × Endocrine × Clear all
NCT04032106 2025-03-14

HPV Vaccine Intervention for Young Sexual Minority Men

Ohio State University Comprehensive Cancer Center

Phase NA Completed
1,227 enrolled 8 charts
Endocrine

Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡